Status:
COMPLETED
Use of NovoSeven® in Active Variceal Bleeding
Lead Sponsor:
Novo Nordisk A/S
Conditions:
Acquired Bleeding Disorder
Cirrhosis
Eligibility:
All Genders
18-79 years
Phase:
PHASE2
Brief Summary
This trial is conducted in Asia and Europe. The trial is planned to investigate the effectiveness and safety of NovoSeven® in patients with advanced cirrhosis and active variceal bleeding.
Eligibility Criteria
Inclusion
- Inclusion Criteria:
- Variceal bleeding
Exclusion
Key Trial Info
Start Date :
April 1 2004
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
August 1 2006
Estimated Enrollment :
265 Patients enrolled
Trial Details
Trial ID
NCT00154492
Start Date
April 1 2004
End Date
August 1 2006
Last Update
January 13 2017
Active Locations (44)
Enter a location and click search to find clinical trials sorted by distance.
1
Novo Nordisk Investigational Site
Vienna, Austria, A 1090
2
Novo Nordisk Investigational Site
Olomouc, Czechia, 77520
3
Novo Nordisk Investigational Site
Prague, Czechia, 12821
4
Novo Nordisk Investigational Site
Prague, Czechia, 140 21